![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
ANAB AnaptysBio
- 17.190
- -0.010-0.06%
Close Feb 25 16:00 ET
523.07MMarket Cap-2.84P/E (TTM)
17.600High16.540Low598.00KVolume17.160Open17.200Pre Close10.28MTurnover3.36%Turnover RatioLossP/E (Static)30.43MShares41.30852wk High6.20P/B306.07MFloat Cap12.21052wk Low--Dividend TTM17.81MShs Float134.000Historical High--Div YieldTTM6.16%Amplitude10.000Historical Low17.184Avg Price1Lot Size
AnaptysBio Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press r...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press r...
74
23
3
$AnaptysBio (ANAB.US)$ FINTEL has it at 33.54% SI! With 200K shares LTB! And live volume just passed 1.5 million! Shorty dont want it going up! Hehehe
8
$AnaptysBio (ANAB.US)$
Clinical Trial Breakthrough: New RA Drug Shows Unprecedented 69% Success Rate, Outperforming Current Treatments
Clinical Trial Breakthrough: New RA Drug Shows Unprecedented 69% Success Rate, Outperforming Current Treatments
$AnaptysBio (ANAB.US)$ AnaptysBio's Rosnilimab Shows Results for Rheumatoid Arthritis, Hits Key Endpoints in Phase 2b Trial
Benzinga
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis (RA). ...
Benzinga
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis (RA). ...
2
$AnaptysBio (ANAB.US)$ Reuters· 1 min ago
AnaptysBio Inc - Rosinilimab Safe and Well Tolerated With Similar Adverse Event Rates Vs Placebo
AnaptysBio Inc - Rosinilimab Safe and Well Tolerated With Similar Adverse Event Rates Vs Placebo
No comment yet
damoose :
Yanfang Kuang : Thank you
74693490 : How much time do you spend on Stocks every day? I remember one time you posted on your Watchlist in the middle of the night, and then at five in the morning the next day you were commenting again. Overextending yourself like this will cause your body to collapse.
Day Lily : Thank you
)
(silent stalker #45,328
Veteran Analyst : Do you use a stock scanner to do the screening? Which software is good? Thanks.
View more comments...